© 2019 Cellular Engineering Technologies.

News Release

Cellular Engineering Technologies, the John Paul II Medical Research Institute and the University of Iowa Create the First Virus-Free and Oncogene-Free Induced Pluripotent Stem Cell (iPSC) Technology to Produce Safer Pluripotent Stem Cells from Cord Blood and Peripheral Blood.
November 30, 2018
CET Has Been Rewarded A Sole Source Navy Contract for Human Amniotic Mesenchymal Stem Cells.

November 3, 2017

Cellular Engineering Technologies and the John Paul II Medical Research Institute Report New Approach to Create Myc and Lin28-Free Induced Pluripotent Stem Cells.

May 12, 2017

Cutting Edge Cancer Technology

KGAN-TV CBS2 News Iowa, June 2014

Iowa Organizations Join Forces to Offer Cutting-Edge Personalized Cancer Diagnosis and Treatment to Patients.

May 2014

 

 

CET Announcing Products for iPS Cell Lines.

January 2013

 

 

CET Announces New Stem Cell Biobank Partnership to Accelerate Drug Discovery.

January 2013

 

 

CET now provides customize induced pluripotent stem (iPS) cell reprograming service and products.

October 2012

 

 

Cellular Engineering Technologies, Inc. (CET) now offers patients-specific Human Bronchial Epithelial cells.

May 2012

 

 

Cellular Engineering Technologies, Inc. (CET) now offers Human
Foreskin Fibroblast (HFF) and Keratinocyte cells.

May 2012

 

 

Federal Grant to Fund Acceleration of New Treatments for Rare
Orphan Diseases.

November 2010

 

 

CET Announces An NIH Intramalls Vendor.

September 2010

 

 

CET Announces A Comprehensive Product Line.

May 2010

 

 

Cellular Engineering Technology Receives DEMO Fund Grant from the Iowa Department of Economic Development (IDED) to Develop Novel Induced Pluripotent Stem Cells.

March 2010

 

 

Cellular Engineering Technologies Inc Receives 2009 Best of Business Award From Small Business Commerce Association.

March 2010